Klaassen D J
Can J Surg. 1978 May;21(3):218-20.
Although considerable research effort has been expanded to improve the drug treatment of colorectal cancer, progress has been slow. 5-fluorouracil (5-FU) is still the agent of choice and no other drug or combination of drugs has been found superior. When combined with radiation therapy 5-FU is superior to irradiation alone in the treatment of localized carcinoma of the rectum. When used as an adjuvant in the management of patients with a poor prognosis after definitive surgical resection, 5-FU has not improved survival or delayed the time to recurrence. Further controlled trials are modalities of therapy to improve these results.
尽管为改善结直肠癌的药物治疗已经投入了大量的研究工作，但进展缓慢。5-氟尿嘧啶（5-FU）仍然是首选药物，尚未发现其他药物或药物组合更具优势。在治疗局部直肠癌时，5-FU与放射治疗联合使用优于单纯放疗。当5-FU用作确定性手术切除后预后不良患者管理的辅助药物时，它并未提高生存率或延迟复发时间。进一步的对照试验是改善这些结果的治疗方式。
